Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers

A Randomized, Open Label, Single Dose, Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of AD-102 in Healthy Male Subjects

The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-102 in healthy male subjects

This study is to evaluate the pharmacokinetic characteristics and safety of AD-102 compared with administration of raloxifen 60 mg + Cholecalciferol 800IU in healthy male subjects

Inclusion Criteria:

• Body mass index (BMI) between 17.5 kg/m2 and 30.5 kg/m2 at the time of screening visit
• The Age between 19 and 50 in healthy male volunteers at the time of screening visit

Exclusion Criteria:

• As a result of laboratory tests, the following figures: ALT or AST> 2 times upper limit of normal range
• As a result of laboratory tests, the following figures: 25-OH vitamin D total <9 ng/mL